Company: BNBX
Filing Date: 2025-01-10
Form Type: S-1/A
Source: 0001104659-25-002521
Chunk: 8

Company: BNB PLUS CORP.
Filing Date: 2025-01-10
Form: S-1/A
Chunk 8
---
 of calendar year 2024,
there were 4,099 gene, cell and RNA therapies in development from preclinical through pre-registration stages, almost all of which use
DNA in their manufacturing process. (Source: ASGCT Gene, Cell & RNA Therapy Landscape: Q3 2024 Quarterly Report). Due to what
we believe are the LineaDNA platform’s numerous advantages over legacy nucleic acid-based therapeutic manufacturing platforms,
we believe this large number of therapies under development represents a substantial market opportunity for the LineaDNA platform to
supplant legacy manufacturing methods in the manufacture of nucleic acid-based therapies although no assurance can be given that we will
be successful in exploiting this market opportunity.

We believe our LineaDNA platform holds several
important advantages over existing cell-based plasmid DNA manufacturing platforms. Plasmid-based DNA manufacturing is based on the complex,
costly and time-consuming biological process of amplifying DNA in living bacterial cells. Once amplified, the DNA must be separated from
the living cells and other process contaminants via multiple rounds of purification, adding further complexity and costs. Unlike plasmid-based
DNA manufacturing, the LineaDNA platform does not require living cells and instead amplifies DNA via the enzymatic process of PCR. The
LineaDNA platform is simple and can rapidly produce very large quantities of DNA without the need for complex purification steps.

We believe the key advantages of the LineaDNA
platform include:

| · | Speed – Production of                                                                            
 LineaDNA can be measured in terms of hours, not days and weeks as is the case with plasmid-based 
 DNA manufacturing platforms.                                                                     |

<div align='center'>2</div>

| · | Scalability –                                                                                                                            
 LineaDNA production takes place on efficient bench-top instruments, allowing for rapid scalability in a minimal footprint.               |
| · | Purity – DNA produced                                                                                                                    
 via PCR is pure, resulting in only large quantities of only the target DNA sequence. Unwanted DNA sequences such as the plasmid backbone 
 and antibiotic resistance genes, inherent to plasmid DNA, are not present in LineaDNA.                                                   |
| · | Simplicity – The                                                                                                                         
 production of LineaDNA is streamlined relative to plasmid-based DNA production. LineaDNA requires only four primary ingredients,         
 does not require living cells or complex fermentation systems and does not require multiple rounds of purification.                      |
| · | Flexibility –                                                                                                                            
 DNA produced via the LineaDNA platform can be